KemPharm Inc. (NASDAQ:KMPH)’s share price rose 12.8% during mid-day trading on Wednesday . The stock traded as high as $5.50 and last traded at $5.37, with a volume of 229,909 shares changing hands. The stock had previously closed at $4.76.

KMPH has been the topic of several research reports. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of KemPharm in a research report on Wednesday, June 8th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday. Finally, Royal Bank Of Canada cut their price target on KemPharm from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, May 6th.

The company’s market cap is $75.13 million. The firm has a 50 day moving average of $4.21 and a 200 day moving average of $10.18.

KemPharm (NASDAQ:KMPH) last posted its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, analysts anticipate that KemPharm Inc. will post ($2.44) earnings per share for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.